MicroRNA Profiling: Increased Expression of MiR-147a and MiR-518e in Progressive Supranuclear Palsy (PSP)

Overview

Journal Neurogenetics

Specialty Neurology

Date 2016 Apr 8

PMID 27052995

Citations 17

Authors

Roman Tatura

Malte Buchholz

Dennis W Dickson

John Van Swieten

Catriona McLean

Gunter Hoglinger

Ulrich Muller

Affiliations

Soon will be listed here.

Abstract

Progressive supranuclear palsy is a sporadic neurodegenerative disorder. Genetic, environmental, and possibly epigenetic factors contribute to disease. In order to better understand the potential role of epigenetic changes in progressive supranuclear palsy, we investigated whether some microRNAs and their target genes are dysregulated. We analyzed expression of 372 well-characterized microRNAs in forebrains of a total of 40 patients and of 40 controls using TaqMan arrays and SYBR Green quantitative real-time PCR. The exploratory cohort included forebrains from 20 patients and 20 controls provided by the Erasmus Medical Centre in Rotterdam, Netherlands. Confirmatory samples were from Jacksonville, Florida, and from Melbourne, Australia. Both microRNA profiling and SYBR Green quantitative real-time PCR revealed significant upregulation of miR-147 (miR-147a) and miR-518e in the exploratory cohort. Highly increased expression of these two microRNAs was validated in the confirmatory samples. Target genes of miR-147a (NF1, ACLY, ALG12) and of miR-518e (CPEB1, JAZF1, RAP1B) were repressed in patients' forebrains. The results suggest that dysregulation of specific microRNAs contributes to disease by repressing target genes involved in various cellular functions.

Citing Articles

The Role of MicroRNAs in Progressive Supranuclear Palsy-A Systematic Review.

Cwiklinska A, Procyk G, Koziorowski D, Szlufik S Int J Mol Sci. 2024; 25(15).

PMID: 39125813 PMC: 11311699. DOI: 10.3390/ijms25158243.

Converging peripheral blood microRNA profiles in Parkinson's disease and progressive supranuclear palsy.

Pavelka L, Rauschenberger A, Hemedan A, Ostaszewski M, Glaab E, Kruger R Brain Commun. 2024; 6(3):fcae187.

PMID: 38863572 PMC: 11166179. DOI: 10.1093/braincomms/fcae187.

Progressive Supranuclear Palsy Syndrome: An Overview.

Ichikawa-Escamilla E, Velasco-Martinez R, Adalid-Peralta L IBRO Neurosci Rep. 2024; 16:598-608.

PMID: 38800085 PMC: 11126858. DOI: 10.1016/j.ibneur.2024.04.008.

Association of Insulin-like Growth Factor-1 and Neurofilament Light Chain in Patients with Progressive Supranuclear Palsy.

Dey S, Yelamanchi R, Mullapudi T, Holla V, Kamble N, Mahale R Ann Indian Acad Neurol. 2024; 27(1):40-45.

PMID: 38495245 PMC: 10941886. DOI: 10.4103/aian.aian_507_23.

Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy.

Simoes F, Joilin G, Peters O, Schneider L, Priller J, Spruth E Int J Mol Sci. 2022; 23(23).

PMID: 36498882 PMC: 9738832. DOI: 10.3390/ijms232314554.

References

Liu G, Friggeri A, Yang Y, Park Y, Tsuruta Y, Abraham E . miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses. Proc Natl Acad Sci U S A. 2009; 106(37):15819-24. PMC: 2747202. DOI: 10.1073/pnas.0901216106. View

Kim K, Kim J, Choi C, Han S, Cheong J, Han S . A role of CPEB1 in the modulation of proliferation and neuronal maturation of rat primary neural progenitor cells. Neurochem Res. 2013; 38(9):1960-72. DOI: 10.1007/s11064-013-1102-4. View

Smith P, Delay C, Girard J, Papon M, Planel E, Sergeant N . MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. Hum Mol Genet. 2011; 20(20):4016-24. DOI: 10.1093/hmg/ddr330. View

Zhao Y, Tseng I, Heyser C, Rockenstein E, Mante M, Adame A . Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis. Neuron. 2015; 87(5):963-75. PMC: 4575284. DOI: 10.1016/j.neuron.2015.08.020. View

Bushati N, Cohen S . microRNA functions. Annu Rev Cell Dev Biol. 2007; 23:175-205. DOI: 10.1146/annurev.cellbio.23.090506.123406. View

Fernandez-Botran R, Ahmed Z, Crespo F, Gatenbee C, Gonzalez J, Dickson D . Cytokine expression and microglial activation in progressive supranuclear palsy. Parkinsonism Relat Disord. 2011; 17(9):683-8. PMC: 3196843. DOI: 10.1016/j.parkreldis.2011.06.007. View

Ziats M, Rennert O . Identification of differentially expressed microRNAs across the developing human brain. Mol Psychiatry. 2013; 19(7):848-52. PMC: 3840150. DOI: 10.1038/mp.2013.93. View

Mestdagh P, Hartmann N, Baeriswyl L, Andreasen D, Bernard N, Chen C . Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat Methods. 2014; 11(8):809-15. DOI: 10.1038/nmeth.3014. View

Neslund-Dudas C, Levin A, Beebe-Dimmer J, Bock C, Nock N, Rundle A . Gene-environment interactions between JAZF1 and occupational and household lead exposure in prostate cancer among African American men. Cancer Causes Control. 2014; 25(7):869-79. PMC: 4267567. DOI: 10.1007/s10552-014-0387-1. View

10.

Darnell J, Richter J . Cytoplasmic RNA-binding proteins and the control of complex brain function. Cold Spring Harb Perspect Biol. 2012; 4(8):a012344. PMC: 3405866. DOI: 10.1101/cshperspect.a012344. View

11.

Grubenmann C, Frank C, Kjaergaard S, Berger E, Aebi M, Hennet T . ALG12 mannosyltransferase defect in congenital disorder of glycosylation type lg. Hum Mol Genet. 2002; 11(19):2331-9. DOI: 10.1093/hmg/11.19.2331. View

12.

Hoglinger G, Melhem N, Dickson D, Sleiman P, Wang L, Klei L . Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011; 43(7):699-705. PMC: 3125476. DOI: 10.1038/ng.859. View

13.

Koontz J, Soreng A, Nucci M, Kuo F, Pauwels P, Van Den Berghe H . Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci U S A. 2001; 98(11):6348-53. PMC: 33471. DOI: 10.1073/pnas.101132598. View

14.

Ratner N, Miller S . A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer. 2015; 15(5):290-301. PMC: 4822336. DOI: 10.1038/nrc3911. View

15.

Raaijmakers J, Bos J . Specificity in Ras and Rap signaling. J Biol Chem. 2008; 284(17):10995-9. PMC: 2670103. DOI: 10.1074/jbc.R800061200. View

16.

Zhang H, Zhang Y, Chen Y, Huang X, Zhou F, Wang W . Appoptosin is a novel pro-apoptotic protein and mediates cell death in neurodegeneration. J Neurosci. 2012; 32(44):15565-76. PMC: 3509748. DOI: 10.1523/JNEUROSCI.3668-12.2012. View

17.

Chypre M, Zaidi N, Smans K . ATP-citrate lyase: a mini-review. Biochem Biophys Res Commun. 2012; 422(1):1-4. DOI: 10.1016/j.bbrc.2012.04.144. View

18.

Stamelou M, de Silva R, Arias-Carrion O, Boura E, Hollerhage M, Oertel W . Rational therapeutic approaches to progressive supranuclear palsy. Brain. 2010; 133(Pt 6):1578-90. DOI: 10.1093/brain/awq115. View

19.

Fernandez-Miranda G, Mendez R . The CPEB-family of proteins, translational control in senescence and cancer. Ageing Res Rev. 2012; 11(4):460-72. DOI: 10.1016/j.arr.2012.03.004. View

20.

Williams D, Lees A . Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 2009; 8(3):270-9. DOI: 10.1016/S1474-4422(09)70042-0. View